Eli Lilly and Co.

Research reforms will force Lilly, others to test how drugs stack upRestricted Content

June 12, 2010
J.K. Wall
The federal government is currently doling out $1.1 billion in stimulus funds to pay for research that compares multiple medical treatments against one another to determine which is most effective. Drug companies like Eli Lilly and Co. are wary that comparative-effectiveness research could threaten their sales.
More

Lilly taps O'Connor as state lobbyist

June 9, 2010
J.K. Wall
O’Connor, chief deputy mayor under former Indianapolis Mayor Bart Peterson, started Monday as Lilly's director of state government affairs—working again under Peterson.
More

Erbitux fails to stop colon cancer before it spreads

June 6, 2010
Bloomberg News
Eli Lilly and Co. and Merck KGaA drug failed to slow tumors in a study designed to expand the medicine's use to patients whose disease is in an earlier stage.
More

Genetic testing could spur Erbitux drug sales

June 1, 2010
Bloomberg News
The drugmakers are counting on screening for the so-called K-ras gene to spur use of Erbitux in metastatic colorectal cancer.
More

Lilly grows Alimta's sales by shrinking marketRestricted Content

May 29, 2010
J.K. Wall
In 2008, Eli Lilly and Co. asked drug regulators to change the label on Alimta so Lilly could no longer promote it as a treatment for all patients suffering from non-small-cell lung cancer, but for only about 70 percent of the patients. Since then, sales of the drug have accelerated, growing a whopping 48 percent last year.
More

Indianapolis startup attacks Alzheimer's diseaseRestricted Content

May 29, 2010
Norm Heikens
AgeneBio Inc. this month landed a $300,000 investment from the Indiana Seed Fund to fund operations, bolster its intellectual property, and begin learning how to make a drug into a once-a-day pill.
More

Eli Lilly invests in $250M Australian venture fund

May 20, 2010
 IBJ Staff and Bloomberg News
The unnamed venture fund will be based in Brisbane, and will focus on biotechnology investments in Australia and southeastern Asia.
More

Drug-spending increase highest in four years

May 20, 2010
Bloomberg News
The price increase was fueled by the debate over the health-care overhaul in Washington, D.C., Medco Health Solutions Inc. CEO David Snow said.
More

Lilly, others cut U.S. tax bills through transfer pricing

May 14, 2010
Bloomberg News
U.S. companies, including Eli Lilly, amassed at least $1 trillion in foreign profits not taxed in the U.S. as of the end of last year. That cumulative total increased 70 percent over three years.
More

Lilly still waiting on once-weekly Byetta

May 12, 2010
J.K. Wall
The U.S. Food and Drug Administration last week pushed its self-declared deadline for rendering an approval decision on the drug Bydureon to Oct. 22. The previous deadline was in March.
More

Lilly hopes Elanco unit becomes a cash cow

May 8, 2010
J.K. Wall
Elanco Animal Health chief Jeff Simmons predicts that consumers will opt for food made cheaper by using Elanco's productivity-enhancing drugs over pricier organic and locally grown products. But, as a hedge, he has Elanco developing products to help organic farmers, too.
More

Latest Lilly job cuts target marketing employees

May 7, 2010
J.K. Wall
Indianapolis-based drugmaker Eli Lilly and Co. is on course to cut 5,500 jobs by the end of 2011 in a bid to eliminate $1 billion in annual expenses.
More

Lilly sues to block copy of Evista osteoporosis drug

May 5, 2010
Bloomberg News
Watson Pharmaceuticals filed for FDA approval to sell a low-cost version of Eli Lilly and Co.'s osteoporosis medicine. Indianapolis-based Lilly is seeking a court order that would block approval until three of its patents expire in 2017.
More

Drug prices rise ahead of rebates

April 21, 2010
J.K. Wall
Drug prices rose faster last year than they have in a decade—just in time for big rebates the drug industry promised as part of the health reform law.
More

Shareholders fail to remove Lilly's anti-takeover provision

April 19, 2010
J.K. Wall
The proposal to remove an 80-percent approval threshold for takeover bids against the wishes of Lilly’s board received approval from shareholders holding 74 percent of Lilly’s shares.
More

Shares fall after Lilly earnings report

April 19, 2010
J.K. Wall
Lilly shareholders are set to gather Monday in Indianapolis to hear an update on the company’s performance, including how it will keep paying its generous dividend during the lean years after Zyprexa’s patent expiration.
More

Lilly to pay $400M to repurchase Cymbalta rights

April 19, 2010
Bloomberg News
Eli Lilly and Co. will repurchase rights to develop and market antidepressant Cymbalta outside the U.S. and Japan from European partner Boehringer Ingelheim for an initial payment of $400 million.
More

Health reform dings Lilly's earnings

April 19, 2010
J.K. Wall
The Indianapolis-based drugmaker also lowered its forecast for full-year profits because the new health care law grants bigger rebates on prescription drugs to federal health insurance programs.
More

Can Lilly afford to maintain its dividend?Restricted Content

April 17, 2010
J.K. Wall
As shareholders gather April 19 for Eli Lilly and Co.'s annual meeting, more of them than ever will come with an unusual question: Will Lilly be able to keep paying its dividend?
More

Lilly sets date for move from Faris campus downtown

April 12, 2010
Work force reductions, new business structure make leased office space unnecessary. Moves will begin in late June.
More

Lilly diabetes drug may have cancer risk, FDA says

April 9, 2010
 IBJ Staff and Bloomberg News
Once-weekly form of Byetta is awaiting the FDA's OK. Analyst predict the new version of the drug, if approved, could rack up sales of $2 billion annually.
More

Louisiana gets $20M in Lilly drug settlement

April 7, 2010
Associated Press
Louisiana was one of 13 states that filed individual suits in state courts over allegations that Lilly pushed Zyprexa for uses that had not been approved by federal regulators.
More

Lilly wins court ban on generic copy of Gemzar

April 1, 2010
Bloomberg News, Associated Press
Eli Lilly and Co. won a U.S. court ruling Wednesday that bars Teva Pharmaceutical Industries Ltd. from selling a generic version of the cancer drug Gemzar until November.
More

Lilly drug wins U.K. backing as cancer therapy

April 1, 2010
Bloomberg News
Eli Lilly and Co.'s Alimta has received the preliminary backing of a United Kingdom agency as a maintenance treatment for patients with the most common form of lung cancer.
More

Lilly to let 115 workers go in new outsourcing deal

March 26, 2010
J.K. Wall
Deal with unit of Massachusetts-based Thermo Fisher Scientific would keep many of the employees working in same location.
More
Page  << 11 12 13 14 15 16 17 18 19 20 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. President Obama has referred to the ACA as "Obamacare" any number of times; one thing it is not, if you don't qualify for a subsidy, is "affordable".

  2. One important correction, Indiana does not have an ag-gag law, it was soundly defeated, or at least changed. It was stripped of everything to do with undercover pictures and video on farms. There is NO WAY on earth that ag gag laws will survive a constitutional challenge. None. Period. Also, the reason they are trying to keep you out, isn't so we don't show the blatant abuse like slamming pigs heads into the ground, it's show we don't show you the legal stuf... the anal electroctions, the cutting off of genitals without anesthesia, the tail docking, the cutting off of beaks, the baby male chicks getting thrown alive into a grinder, the deplorable conditions, downed animals, animals sitting in their own excrement, the throat slitting, the bolt guns. It is all deplorable behavior that doesn't belong in a civilized society. The meat, dairy and egg industries are running scared right now, which is why they are trying to pass these ridiculous laws. What a losing battle.

  3. Eating there years ago the food was decent, nothing to write home about. Weird thing was Javier tried to pass off the story the way he ended up in Indy was he took a bus he thought was going to Minneapolis. This seems to be the same story from the founder of Acapulco Joe's. Stopped going as I never really did trust him after that or the quality of what being served.

  4. Indianapolis...the city of cricket, chains, crime and call centers!

  5. "In real life, a farmer wants his livestock as happy and health as possible. Such treatment give the best financial return." I have to disagree. What's in the farmer's best interest is to raise as many animals as possible as quickly as possible as cheaply as possible. There is a reason grass-fed beef is more expensive than corn-fed beef: it costs more to raise. Since consumers often want more food for lower prices, the incentive is for farmers to maximize their production while minimizing their costs. Obviously, having very sick or dead animals does not help the farmer, however, so there is a line somewhere. Where that line is drawn is the question.

ADVERTISEMENT